

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION**

DISTRICT OFFICE ADDRESS AND PHONE NUMBER 12420 Parklawn Drive, Room 2032 Rockville, MD 20857 Industry Information: www.fda.gov/oc/industry	DATE(S) OF INSPECTION 10/22-26/2018 FEI NUMBER 3004161218
--	--

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED
TO: Janmejy R. Vyas, Chairman

FIRM NAME Dishman Carbogen Amcis Ltd	STREET ADDRESS Survey No. 47, Paiki Sub Plot No. 1, Lodariyal Sanand-Bavla
CITY, STATE AND ZIP CODE Ahmedabad 382 220, Gujarat, India	TYPE OF ESTABLISHMENT INSPECTED API Manufacturer

THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.

DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:

PRODUCTION SYSTEM

1.) Blending of in-specification with out-of-specification (OOS) intermediate batches is performed.

Specifically, (b)(4) (intermediate) batch (b)(4) tested OOS for impurity (b)(4). The batch was manufactured starting on 03/05/2018. QC testing of this batch yielded a result of (b)(4) % for the impurity against a specification of less than or equal to (b)(4) %. Deviation investigation DV (b)(4) /1801, written for this incident, calls for this batch to be blended with other batches that have an in-specification result for (b)(4) manufacturing. The OOS batch was blended with in-specification material as follows:

- A.) (b)(4) kg of batch (b)(4) blended with (b)(4) kg of batch (b)(4) to manufacture (b)(4) batch (b)(4)
- B.) (b)(4) kg (b)(4) blended with (b)(4) kg of batch (b)(4) and (b)(4) kg of batch (b)(4) to manufacture (b)(4) batch (b)(4)
- C.) (b)(4) kg of batch (b)(4) blended with (b)(4) kg of batch (b)(4) to manufacture (b)(4) batch (b)(4)
- D.) (b)(4) kg of batch (b)(4) blended with (b)(4) kg of batch (b)(4) and (b)(4) kg of batch (b)(4) to manufacture (b)(4) batch (b)(4)

The manufactured (b)(4) batches were used in the production of packaged lots (b)(4) of (b)(4).

LABORATORY CONTROL SYSTEM

2.) Laboratory investigations for OOS intermediate batches are not conducted.

Specifically, according to SOP BDQC-311 for OOS investigations (effective 07/16/2018), OOS is to be conducted on "...all quantitative and qualitative tests of...intermediates..." An investigation of an OOS impurity result in the (b)(4) intermediate, batch (b)(4) for (b)(4) was not conducted.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Alan P. Kurtzberg -S	EMPLOYEE(S) NAME AND TITLE (Print or Type) Alan P. Kurtzberg, Investigator	DATE ISSUED 10/26/2018
	Digitally signed by Alan P. Kurtzberg -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=200140310 2, cn=Alan P. Kurtzberg -S Date: 2018.10.26 10:40:31 +05'30'		